CONFERENCE UPDATE: ASCO 2022

PARADIGM: Panitumumab + mFOLFOX6 vs. bevacizumab + mFOLFOX6 as 1L treatment in RAS WT mCRC patients

GASTROENTEROLOGY & HEPATOLOGY ONCOLOGY
29 Jul 2022

Glossary: 1L: First-line; AEs: Advaerse events; CI: Confidence interval; DCR: Disease control rate; DoR: Duration of response; ECOG: Eastern Cooperation Oncology Group; ETS: Early tumor shrinkage; HR: Hazard ratio; IV: Intravenous; LE: Life expectancy; mCRC: Metastatic colorectal cancer; OS: Overall survival; PFS: Progression-free survival; PS: Performance status; Q2W: Every 2 weeks; R0: Curative resection; RR: Response rate

Get access to our exclusive articles.
Related Articles

Sotorasib-panitumumab shows efficacy against KRAS G12C-mutated mCRC

In the recent CodeBreaK 101 study, sotorasib, in combination with panitumumab, has been demonstrated to be safe and effective among patients with chemorefractory Kirsten rat sarcoma virus (KRAS) G12C-mutated metastatic colorectal cancer (mCRC).1 The positive results showed promise of this novel combination therapy as a new standard of care (SoC) for the treatment of KRAS G12C-mutated mCRC.1
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY
04 Jan 2023